Ademar Dantas da Cunha Junior

Dr. Ademar Dantas da Cunha Junior

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2025 in Blood
Verified
Journal Article
Open access
DKDavid John Kuter
David John Kuter
WGWaleed Ghanima
Waleed Ghanima
NCNichola Cooper
Nichola Cooper
HLHoward A. Liebman
Howard A. Liebman
LZLei Zhang
Lei Zhang
ADAhmed Daak
Ahmed Daak
Rilzabrutinib is a covalent, reversible Bruton tyrosine kinase inhibitor targeting multiple immune thrombocytopenia (ITP)-related mechanisms. The phase 3 LUNA3 study in previously treated adults with persistent/chronic ITP evaluated oral rilzabrutinib 400 mg twice daily (n = 133) vs placebo (n = 69) for 24 weeks. At baseline overall, median age was 47 years, 63% female, 7.7 year median ITP duration, and 28% prior splenectomy. Overall (N = 202), 85 (64%) rilzabrutinib and 22 (32%) placebo patients achieved platelet response (≥50 × 109/L or 30 × 109/L to <50 × 109/L and doubled from baseline) during the first 12 weeks and were eligible to continue. The primary end point, durable platelet response (platelet count ≥50 × 109/L for ≥two-thirds of ≥8 of the last 12 of 24 weeks without rescue therapy), was observed in 31 (23%) rilzabrutinib vs 0 placebo patients (P < .0001). All secondary efficacy end points were significantly superior for rilzabrutinib (P < .05). Median time to first platelet response was 15 days in rilzabrutinib responders. Rilzabrutinib significantly reduced rescue therapy use by 52% (P = .0007) and improved week 25 bleeding scores (P = .0006). Improved physical fatigue was sustained from week 13 (P = .01) through 25 (P = .0003). Treatment-related adverse events were mainly grade 1/2. One rilzabrutinib patient with multiple risk factors had serious treatment-related grade 3 peripheral embolism (lower left leg), and another died from unrelated pneumonia. Rilzabrutinib in patients who failed multiple previous ITP therapies showed rapid and durable platelet response, reduced rescue medication and bleeding, improved physical fatigue, and favorable safety. Trial registration: www.clinicaltrials.gov (#NCT04562766) and www.clinicaltrialsregister.eu (#2020-002063-60).

7 May 2021 in World Journal of Gastroenterology
Verified
Journal Article
Open access
Ademar Dantas da Cunha JuniorAdemar Dantas da Cunha Junior
Ademar Dantas da Cunha Junior
ABArinilda Campos Bragagnoli
Arinilda Campos Bragagnoli
FCFelipe Osório Costa
Felipe Osório Costa
JCJosé Carvalheira
José Carvalheira
Repurposing metformin for the treatment of gastrointestinal cancer

18 January 2021 in Advances in Hematology
Verified
Journal Article
Open access
PDF file
Ademar Dantas da Cunha JuniorAdemar Dantas da Cunha Junior
Ademar Dantas da Cunha Junior
DZDalila Luciola Zanette
Dalila Luciola Zanette
FPFernando Vieira Pericole
Fernando Vieira Pericole
SSSARA Teresinha OLALLA SAAD
SARA Teresinha OLALLA SAAD
JCJosé Carvalheira
José Carvalheira
Obesity is increasingly associated with the transformation of monoclonal gammopathy of undetermined significance (MGUS) into multiple myeloma (MM). Obesity, MGUS, and MM share common etiopathogenesis mechanisms including altered insulin axis and the action of inflammatory cytokines. Consistent with this interconnection, metformin could predominantly exert inhibition of these pathophysiological factors and thus be an attractive therapeutic option for MGUS. Despite the possible clinical significance, only a limited number of epidemiological studies have focused on obesity as a risk factor for MGUS and MM. This review describes multiple biological pathways modulated by metformin at the cellular level and their possible impacts on the biology of MGUS and its progression into MM.

27 October 2025 in Onco
Verified
Journal Article
Open access
PDF file
Ademar Dantas da Cunha JuniorAdemar Dantas da Cunha Junior
Ademar Dantas da Cunha Junior
LCLarissa Ariel Oliveira Carrilho
Larissa Ariel Oliveira Carrilho
PFPaulo Ricardo Santos Nunes Filho
Paulo Ricardo Santos Nunes Filho
LCLuca Cantini
Luca Cantini
LVLaura Vidal
Laura Vidal
KSKamal S. Saini
Kamal S. Saini
The inflammatory milieu surrounding tumors plays a pivotal yet paradoxical role in promoting carcinogenesis. Rather than simply acting as a host defense mechanism, chronic low-grade inflammation actively nurtures tumor development and supports hallmarks such as sustained proliferative signaling, apoptosis resistance, angiogenesis, and metastasis. Obesity, characterized by a chronic inflammatory state, exacerbates this tumor-promoting environment through metabolic imbalances like insulin resistance, hyperglycemia, and dyslipidemia. These conditions stimulate oncogenic signaling pathways and reshape the tumor microenvironment. Obesity-associated cytokines, altered adipokines, and insulin-related growth signals synergistically enhance processes such as epithelial-to-mesenchymal transition (EMT) and matrix remodeling. This review explores the mechanistic interplay between obesity-induced inflammation and insulin resistance in cancer progression, discusses the molecular pathways involved, and highlights emerging therapeutic approaches targeting these intersecting tumor promotion axes.

21 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Ademar Dantas da Cunha JuniorAdemar Dantas da Cunha Junior
Ademar Dantas da Cunha Junior
LCLarissa Ariel Oliveira Carrilho
Larissa Ariel Oliveira Carrilho
PFPaulo Ricardo Santos Nunes Filho
Paulo Ricardo Santos Nunes Filho
LCLuca Cantini
Luca Cantini
LVLaura Vidal
Laura Vidal
KSKamal S. Saini
Kamal S. Saini
The inflammatory milieu surrounding tumors plays a pivotal yet paradoxical role in promoting carcinogenesis. Rather than simply acting as a host defense mechanism, chronic low-grade inflammation actively nurtures tumor development and supports hallmarks such as sustained proliferative signaling, apoptosis resistance, angiogenesis, and metastasis. Obesity, characterized by a chronic inflammatory state, exacerbates this tumor-promoting environment through metabolic imbalances like insulin resistance, hyperglycemia, and dyslipidemia. These conditions stimulate oncogenic signaling pathways and reshape the tumor microenvironment. Obesity-associated cytokines, altered adipokines, and insulin-related growth signals synergistically enhance processes such as epithelial-to-mesenchymal transition (EMT) and matrix remodeling. This review explores the mechanistic interplay between obesity-induced inflammation and insulin resistance in cancer progression, discusses the molecular pathways involved, and highlights emerging therapeutic approaches targeting these intersecting tumor promotion axes.

5 November 2024 in Blood
Verified
Journal Article
Closed access
Ademar Dantas da Cunha JuniorAdemar Dantas da Cunha Junior
Ademar Dantas da Cunha Junior
KSKamal Veer Saini
Kamal Veer Saini
LBLaura Vidal Boixader
Laura Vidal Boixader
AOAna Flavia Redolfi Oliota
Ana Flavia Redolfi Oliota
MBMayara Pryscila Borsa
Mayara Pryscila Borsa
BHBrian Hamilton
Brian Hamilton
Background: Monoclonal gammopathy of undetermined significance (MGUS) is marked by the asymptomatic proliferation of monoclonal plasma cells, which sometimes precedes multiple myeloma (MM), a bone marrow malignancy primarily affecting individuals over 50 years old and accounting for 10% of hematological cancers globally. While the etiology of MGUS remains largely unclear, there is evidence suggesting that pesticide exposure may contribute to the development of this condition, especially among rural workers due to their frequent exposure to such substances. The prevalence of MGUS varies globally, estimated at 3-4% in individuals over 50, but higher in agricultural areas due to pesticide exposure. The western region of Parana is one of the main areas for pesticide use in Brazil. In 2017, the state of Paraná accounted for 16% of the total pesticide usage in the country, making it the third-largest national consumer. In Brazil, pesticide use reached 10.9 kg per hectare, significantly higher than the 2.85 kg/ha in the USA and 1.9 kg/ha in China. These data highlight the intensity of pesticide use in Parana's agriculture compared to the rest of Brazil and the world. This study focuses on the western macro-region of Parana State, Brazil, known for intensive agriculture and significant pesticide use, contributing 23% to the state's agricultural production value in 2018. Trial design: This epidemiological, observational, case-control study aims to assess the prevalence and the association between direct pesticide exposure and the presence of MGUS, emphasizing the identification of key risk factors. The study population includes men over the age of 50, divided into two groups: the case group, consisting of individuals with a history of occupational pesticide exposure (pesticide applicators), and the control group (non-pesticide applicators), representing the general community population. The study aims to enroll 480 participants, with 240 in each group. Ethical approval was granted by the Human Research Ethics Committee (number 5.794.378), data is being collected from September 2023 up to September 2025. Laboratory tests, including protein electrophoresis, immunofixation, and freelite assays, serve as primary endpoints. A regression analysis will evaluate factors related to MGUS risk, considering independent variables such as age, race, weight, health history, comorbidities, medications, family health history, and detailed pesticide exposure information (type, duration, specific pesticides used, crops treated, and PPE use). The analysis adopts a 95% confidence level and a two-sided significance level of 5%. By comparing the odd risk of exposed individuals to a control group, the study seeks to provide valuable insights into the potential risks associated MGUS with pesticide exposure.